This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.

The new devices, which monitor neural activity from within blood vessels, show long-term stability in rats and could one day deliver electrical stimulation.

This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.

A text-predicting chatbot parses text from conversations in a way that parallels brain-activity patterns associated with speech production and comprehension.

Next-generation trackers could realize a long-standing research dream: conducting sleep studies in large numbers of autistic people.

The tool connects to electrodes implanted in people with epilepsy or other brain conditions and can monitor and regulate neurons during everyday activities.

The treatment eases the animals’ sleep troubles, suggesting it has clinically meaningful effects beyond what was thought to be a critical window in early life.

The transplanted cells integrate into living animals’ neural circuitry and influence behavior.

Null and replicated results in this month’s newsletter tackle aging, a purported pathway for oxytocin’s effects on autistic people, and a possible autism biomarker.

This week, we’re bringing you some labors of love: a thread lamenting the autism field’s focus on gene lists, a study introducing genetic diversity in mouse models, and long-awaited results from a biomarker study.